Barry Greene, Sage CEO (Adrien Villez for Endpoints News)
Sage focuses on successful launch of postpartum depression drug
Sage Therapeutics is doubling down on the “blockbuster potential” of its postpartum depression drug Zurzuvae, expanding professional promotions and taking steps toward a direct-to-consumer launch …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.